Enorama Pharma's market value is the price at which a share of Enorama Pharma trades on a public exchange. It measures the collective expectations of Enorama Pharma AB investors about its performance. Enorama Pharma is selling for under 0.67 as of the 3rd of March 2026; that is 11.84 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 0.67. With this module, you can estimate the performance of a buy and hold strategy of Enorama Pharma AB and determine expected loss or profit from investing in Enorama Pharma over a given investment horizon. Check out Enorama Pharma Correlation, Enorama Pharma Volatility and Enorama Pharma Performance module to complement your research on Enorama Pharma.
It's important to distinguish between Enorama Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Enorama Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Enorama Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Enorama Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Enorama Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Enorama Pharma.
0.00
12/03/2025
No Change 0.00
0.0
In 3 months and 1 day
03/03/2026
0.00
If you would invest 0.00 in Enorama Pharma on December 3, 2025 and sell it all today you would earn a total of 0.00 from holding Enorama Pharma AB or generate 0.0% return on investment in Enorama Pharma over 90 days. Enorama Pharma is related to or competes with Klaria Pharma, Isofol Medical, Annexin Pharmaceuticals, Clinical Laserthermia, SenzaGen, IZafe Group, and Integrum. Enorama Pharma AB , a pharmaceutical company, develops, manufactures, and sells medicated chewing gum containing proven ... More
Enorama Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Enorama Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Enorama Pharma AB upside and downside potential and time the market with a certain degree of confidence.
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enorama Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Enorama Pharma's standard deviation. In reality, there are many statistical measures that can use Enorama Pharma historical prices to predict the future Enorama Pharma's volatility.
Enorama Pharma AB secures Sharpe Ratio (or Efficiency) of -0.0481, which denotes the company had a -0.0481 % return per unit of risk over the last 3 months. Enorama Pharma AB exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Enorama Pharma's Variance of 250.8, standard deviation of 15.84, and Mean Deviation of 9.14 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 3.23, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Enorama Pharma will likely underperform. At this point, Enorama Pharma AB has a negative expected return of -0.81%. Please make sure to confirm Enorama Pharma's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to decide if Enorama Pharma AB performance from the past will be repeated at some point in the near future.
Auto-correlation
0.56
Modest predictability
Enorama Pharma AB has modest predictability. Overlapping area represents the amount of predictability between Enorama Pharma time series from 3rd of December 2025 to 17th of January 2026 and 17th of January 2026 to 3rd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Enorama Pharma AB price movement. The serial correlation of 0.56 indicates that roughly 56.0% of current Enorama Pharma price fluctuation can be explain by its past prices.
Correlation Coefficient
0.56
Spearman Rank Test
0.64
Residual Average
0.0
Price Variance
0.14
Thematic Opportunities
Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
When running Enorama Pharma's price analysis, check to measure Enorama Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enorama Pharma is operating at the current time. Most of Enorama Pharma's value examination focuses on studying past and present price action to predict the probability of Enorama Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enorama Pharma's price. Additionally, you may evaluate how the addition of Enorama Pharma to your portfolios can decrease your overall portfolio volatility.